FDA Pharmacoepidemiology Office Adds Jonca Bull
This article was originally published in The Pink Sheet Daily
Executive Summary
ODE V director joins effective May 2 as deputy director, leaving only one major vacancy in OPaSS. Reorganization of the Office of New Drugs is eliminating ODE V.
You may also be interested in...
Jonca Bull Brings Clinical Experience To FDA Minority Health Office
Bull returns to the agency after stints at Novartis and Genentech to become director of the Office of Minority Health.
FDA Gastroenterology Drugs Division Headed By Harvey; Phase-Out Of ODE V Complete
Harvey brings GI experience from the device center as former Gastroenterology & Renal Devices Branch reviewer. His appointment comes as FDA is eliminating the Office of Drug Evaluation V under the reorganization of the Office of New Drugs.
FDA Gastroenterology Drugs Division Headed By Harvey; Phase-Out Of ODE V Complete
Harvey brings GI experience from the device center as former Gastroenterology & Renal Devices Branch reviewer. His appointment comes as FDA is eliminating the Office of Drug Evaluation V under the reorganization of the Office of New Drugs.